158 related articles for article (PubMed ID: 3556201)
1. Synthesis of enkephalinase B inhibitors, and their activity on isolated enkephalin-degrading enzymes.
Van Amsterdam JG; Van Buuren KJ; Blad MW; Soudijn W
Eur J Pharmacol; 1987 Mar; 135(3):411-8. PubMed ID: 3556201
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of enkephalin degrading enzymes by metal chelating reagents.
Altstein M; Blumberg S; Vogel Z
Adv Biochem Psychopharmacol; 1982; 33():261-70. PubMed ID: 6751033
[TBL] [Abstract][Full Text] [Related]
3. Protection of enkephalins from enzymatic degradation utilizing selective metal-chelating inhibitors.
Altstein M; Bachar E; Vogel Z; Blumberg S
Eur J Pharmacol; 1983 Aug; 91(4):353-61. PubMed ID: 6352283
[TBL] [Abstract][Full Text] [Related]
4. New carboxyalkyl inhibitors of brain enkephalinase: synthesis, biological activity, and analgesic properties.
Fournié-Zaluski MC; Chaillet P; Soroca-Lucas E; Marçais-Collado H; Costentin J; Roques BP
J Med Chem; 1983 Jan; 26(1):60-5. PubMed ID: 6298420
[TBL] [Abstract][Full Text] [Related]
5. Selective protection of methionine enkephalin released from brain slices by enkephalinase inhibition.
Patey G; De La Baume S; Schwartz JC; Gros C; Roques B; Fournie-Zaluski MC; Soroca-Lucas E
Science; 1981 Jun; 212(4499):1153-5. PubMed ID: 7015510
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of calf-brain enkephalinase A and B.
van Amsterdam JG; van Buuren KJ; de Jong AM; Soudijn W
Life Sci; 1983; 33 Suppl 1():109-12. PubMed ID: 6363851
[TBL] [Abstract][Full Text] [Related]
7. Effect of inhibitors of enkephalin degradation in the isolated guinea-pig ileum.
van Amsterdam JG; van Buuren KJ; Krielaart MJ; Zuiderveld OP; Tijms RP
Life Sci; 1988; 43(19):1529-36. PubMed ID: 3193845
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo effects of kelatorphan on enkephalin metabolism in rodent brain.
Waksman G; Bouboutou R; Devin J; Bourgoin S; Cesselin F; Hamon M; Fournie-Zaluski MC; Roques B
Eur J Pharmacol; 1985 Nov; 117(2):233-43. PubMed ID: 3865779
[TBL] [Abstract][Full Text] [Related]
9. Phelorphan, an inhibitor of enzymes involved in the biodegradation of enkephalins, affected the withdrawal symptoms in chronic morphine-dependent rats.
Haffmans J; Walsum MV; van Amsterdam JC; Dzoljic MR
Neuroscience; 1987 Jul; 22(1):233-6. PubMed ID: 2888045
[TBL] [Abstract][Full Text] [Related]
10. Composite effects of actinonin when inhibiting enkephalin-degrading enzymes.
Hachisu M; Hiranuma T; Shibazaki Y; Uotani K; Murata S; Aoyagi T; Umezawa H
Eur J Pharmacol; 1987 May; 137(1):59-65. PubMed ID: 2886348
[TBL] [Abstract][Full Text] [Related]
11. Analgesic effects of kelatorphan, a new highly potent inhibitor of multiple enkephalin degrading enzymes.
Fournie-Zaluski MC; Chaillet P; Bouboutou R; Coulaud A; Cherot P; Waksman G; Costentin J; Roques BP
Eur J Pharmacol; 1984 Jul; 102(3-4):525-8. PubMed ID: 6386492
[TBL] [Abstract][Full Text] [Related]
12. Differences in the structural requirements for selective interaction with neutral metalloendopeptidase (enkephalinase) or angiotensin-converting enzyme. Molecular investigation by use of new thiol inhibitors.
Fournie-Zaluski MC; Lucas E; Waksman G; Roques BP
Eur J Biochem; 1984 Mar; 139(2):267-74. PubMed ID: 6321177
[TBL] [Abstract][Full Text] [Related]
13. Analgesic effect of actinonin, a new potent inhibitor of multiple enkephalin degrading enzymes.
Hachisu M; Hiranuma T; Murata S; Aoyagi T; Umezawa H
Life Sci; 1987 Jul; 41(2):235-40. PubMed ID: 3298909
[TBL] [Abstract][Full Text] [Related]
14. Differential recognition of "enkephalinase" and angiotensin-converting enzyme by new carboxyalkyl inhibitors.
Fournié-Zaluski MC; Soroca-Lucas E; Waksman G; Llorens C; Schwartz JC; Roques BP
Life Sci; 1982 Dec; 31(26):2947-54. PubMed ID: 6298535
[TBL] [Abstract][Full Text] [Related]
15. A highly sensitive fluorometric assay for "enkephalinase," a neutral metalloendopeptidase that releases tyrosine-glycine-glycine from enkephalins.
Florentin D; Sassi A; Roques BP
Anal Biochem; 1984 Aug; 141(1):62-9. PubMed ID: 6388410
[TBL] [Abstract][Full Text] [Related]
16. [Enkephalinase inhibitors and molecular study of the differences between active sites of enkephalinase and angiotensin-converting enzyme].
Roques BP
J Pharmacol; 1985; 16 Suppl 1():5-31. PubMed ID: 2993752
[TBL] [Abstract][Full Text] [Related]
17. Complete differentiation between enkephalinase and angiotensin-converting enzyme inhibition by retro-thiorphan.
Roques BP; Lucas-Soroca E; Chaillet P; Costentin J; Fournié-Zaluski MC
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3178-82. PubMed ID: 6304695
[TBL] [Abstract][Full Text] [Related]
18. Effect of various enkephalin analogs and dipeptides on the enzymatic activity of enkephalinase B isolated from calf-brain striatum.
van Amsterdam JG; van Buuren KJ; Koomen AP; Soudijn W
Life Sci; 1986 Mar; 38(12):1111-8. PubMed ID: 3515091
[TBL] [Abstract][Full Text] [Related]
19. Propioxatins A and B, new enkephalinase B inhibitors. IV. Characterization of the active site of the enzyme using synthetic propioxatin analogues.
Inaoka Y; Naruto S
J Biochem; 1988 Nov; 104(5):706-11. PubMed ID: 3069842
[TBL] [Abstract][Full Text] [Related]
20. Enkephalin-degrading dipeptidylaminopeptidase: characterization of the active site and selective inhibition.
Chérot P; Devin J; Fournié-Zaluski MC; Roques BP
Mol Pharmacol; 1986 Oct; 30(4):338-44. PubMed ID: 3531805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
